

Ghrelin may predict cognitive impairment

October 10 2016



(HealthDay)—Blood levels of ghrelin may be a predictor of executive function impairment in patients with type 2 diabetes mellitus (T2DM), according to a study published online Sept. 30 in the *Journal of Diabetes*



Investigation.

Siting Chen, M.D., from Anhui Medical University in Hefei, China, and colleagues analyzed ghrelin levels in blood samples from 212 patients with T2DM and 158 controls.

The researchers found that age, education year, duration of diabetes, fasting <u>blood glucose</u>, glycated hemoglobin, hypertension, and waist-tohip ratio were correlated with total Montreal Cognitive Assessment (MoCA) scores in the T2DM group. There was no association between ghrelin level and total MoCA score in patients with T2DM. However, ghrelin was a significant predictor for executive function impairment in patients with T2DM measured by the Wisconsin Card Sorting Test.

"The level of serum ghrelin might be a biomarker of executive function and become a strong predictor of executive function impairment in patients with T2DM," the authors write. "Ghrelin might have a potential protective effect against cognitive function impairment in type 2 diabetic patients."

More information: <u>Abstract</u> <u>Full Text</u>

Copyright © 2016 HealthDay. All rights reserved.

Citation: Ghrelin may predict cognitive impairment (2016, October 10) retrieved 1 May 2024 from <u>https://medicalxpress.com/news/2016-10-ghrelin-cognitive-impairment.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.